Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) has released its Sustainability Report 2025–26, highlighting progress across environmental performance, quality, people, governance and community initiatives. Released under the theme “Advancing Innovation, Leveraging Sustainability”, the report outlines the company’s approach to integrating sustainability into its operations and business strategy. The company has reported a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with its FY2022 baseline.
Renewable energy accounted for 41% of total energy consumption across Piramal Pharma’s operations during the reporting period. The company also recycled and reused 2.63 lakh kilolitres of freshwater and diverted 65% of its total waste for recycling. Piramal Pharma said it continued to implement its Science Based Targets initiative-approved decarbonisation roadmap while strengthening operational efficiency and environmental practices.
Quality and regulatory compliance remained key areas of focus. During FY2025–26, the company successfully completed 38 regulatory inspections, including three USFDA inspections with zero Official Action Indicated observations. It also completed 209 customer audits across its global manufacturing network.
The company continued its digital transformation through initiatives including Catalyst NxGen, SAP S/4HANA implementation and the expansion of digital quality systems. Piramal Pharma also announced a US$90 million investment to expand advanced therapeutics capabilities at its Lexington and Riverview facilities.
Nandini Piramal, Chairperson, Piramal Pharma Limited, said sustainability is being treated as a driver of innovation, resilience and long-term growth. “At Piramal Pharma, we see sustainability not simply as a responsibility, but as a catalyst for innovation, resilience and long-term growth. This means investing in cleaner and more efficient operations, strengthening quality and digital capabilities, developing our people and building deeper partnerships across our value chain,” she said.
The company reported zero data breach incidents and zero corruption cases during the year. ESG training was completed by 100% of employees, while 100% of the workforce completed Code of Conduct training. Women accounted for 30% of the company’s Board and 20.1% of its global workforce. Piramal Pharma also assessed 38% of its critical suppliers against sustainability criteria as part of its responsible supply chain programme. Community development remained another major focus. During FY2025–26, the company invested ₹8.98 crore in CSR initiatives and reported reaching nearly 1.8 million people across 112 Aspirational Districts through healthcare and education programmes.
Piramal Pharma’s sustainability framework is built around four pillars: Business Resilience, Quality & Excellence, Responsible Operations and Stakeholder Centricity. These are supported by more than 50 time-bound sustainability targets covering 17 material topics.
The company’s Sustainability and Risk Management Committee oversees the sustainability agenda and helps ensure ESG considerations remain part of its long-term business planning. The Sustainability Report follows GRI standards and is aligned with SASB and UN Global Compact frameworks.
Piramal Pharma operates through 17 global development and manufacturing facilities and a distribution network covering more than 100 countries. Its businesses include Piramal Pharma Solutions, Piramal Critical Care and Piramal Consumer Healthcare, covering contract development and manufacturing, complex hospital generics, and consumer healthcare products.
